E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Fistulizing Crohn?s Disease (CD) |
Enfermedad de Crohn (EC) fistulizante |
|
E.1.1.1 | Medical condition in easily understood language |
Crohn?s disease is an inflammatory disease of the gastrointestinal tract. |
La Enfermedad de Crohn es una enfermedad inflamatoria del tracto gastrointestinal |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10075465 |
E.1.2 | Term | Fistulizing Crohn's disease |
E.1.2 | System Organ Class | 100000004856 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to evaluate the proportion of subjects with fistula healing at Week 30 in 2 different dose regimens of vedolizumab IV 300mg in subjects with fistulizing CD. |
El objetivo primario es evaluar la proporcion de sujetos con curacion de una o mas fistulas en la semana 30 con dos regímenes diferentes de dosis de vedolizumab i.v. 300 mg en sujetos con Enfermedad de Crohn. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objective is to evaluate fistula healing over a 30-week evaluation period. |
El objetivo secundario es evaluar la curación de las fístulas a lo largo de un periodo de 30 semanas. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
-Adult subjects, aged 18 to 80 years, inclusive, with moderately to severely active CD and 1 to 3 draining perianal fistula(e) of at least 2 weeks duration. -Subjects who have historically had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-alfa antagonist for their underlying CD (does not require treatment failure for currently active draining fistula). -Noncutting seton placement as part of standard of care within 1 to 4 weeks prior to randomization. |
-Sujetos adultos, de entre 18 y 80 años de edad, ambos inclusive, con EC con actividad de moderada a muy grave y con entre 1 y 3 fístulas perianales drenantes de al menos dos semanas de duración. -Sujetos que han presentado en el pasado una respuesta inadecuada, una pérdida de respuesta o una intolerancia al tratamiento convencional o a un antagonista del FNT-alfa administrado para tratar su EC subyacente (no requiere fracaso del tratamiento para la fístula drenante activa actual). -Colocación de un setón sin realizar corte, como parte de la atención de rutina, entre 1 y 4 semanas antes de la aleatorización. |
|
E.4 | Principal exclusion criteria |
-Subjects who have perianal abscesses greater than 2 cm or an abscess that the investigator feels requires drainage based on either clinical assessment or MRI. -Subjects who have a CDAI score greater than 400. -Subjects who have ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine. -Subjects who have significant anal or rectal stenosis. -Subjects who have any evidence of an active infection (eg, sepsis, cytomegalovirus, or listeriosis) during Screening, other than related to the fistula(e). -Subjects who have a positive progressive multifocal leukoencephalopathy (PML) subjective checklist. -Subjects who have received any investigational or approved biologic or biosimilar agent within 60 days or 5 half-lives of randomization (whichever is longer). -Subjects who have had prior exposure to vedolizumab, natalizumab, efalizumab, or rituximab. |
-Sujetos con abscesos perianales de más de 2 cm o un absceso que el investigador considera que requiere drenaje en base a la evaluación clínica o a la RM. -Sujetos con una puntuación CDAI superior a 400. -Sujetos con una ileostomía, colostomía o con una estenosis intestinal sintomática conocida. -Sujetos con una estenosis anal o rectal significativa. -Sujetos que presenten evidencia de infección activa (p. ej., septicemia, citomegalovirus o listeriosis) durante la Selección, aparte de la infección asociada a la fístula o fístulas. -Sujetos con resultado positivo en una lista de verificación subjetiva para leucoencefalopatía multifocal progresiva (LMP). -Sujetos que han recibido cualquier fármaco biológico o biosimilar aprobado o en investigación en los 60 días o 5 semividas (lo que sea más largo) posteriores a la aleatorización. -Sujetos que han recibido previamente vedolizumab, natalizumab, efalizumab o rituximab. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint for this study is the proportion of subjects with a reduction of at least 50% from Day 1 in the number of draining fistulae at Week 30 (where closed fistulae are no longer draining despite gentle finger compression). |
La principal valoración de este estudio es la proporción de sujetos con una reducción de al menos el 50 porciento en el número de fístulas drenantes en la semana 30 en comparación con el día 1 (donde las fístulas cerradas no drenan aunque se ejerza una leve presión con el dedo). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At week 30 |
En la semana 30 |
|
E.5.2 | Secondary end point(s) |
-The proportion of subjects with 100% fistulae closure at Week 30 (where all fistulae are no longer draining despite gentle finger compression). -Time to first fistula closure. -Time to last (100%) fistulae closure. -Duration of fistula response (number of days with drainage) |
-La proporción de sujetos con cierre del 100 porcien de las fístulas en la semana 30 (donde no drena ninguna fístula aunque se ejerza una leve presión con el dedo). -Tiempo hasta el cierre de la primera fístula. -Tiempo hasta el cierre de la última (100 %) fístula. -Duración de la respuesta fistular (p.ej., número de días con drenaje). |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
30 week period |
Periodo de 30 semanas |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 15 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belgium |
Canada |
France |
Italy |
Netherlands |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of trial will be the date of the last visit of the last subject at the Week 40 Follow-up Visit |
El fin del ensayo será la fecha de la última visita del último paciente en la semana 40, Visita de Seguimiento. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |